Drugs / HRS9950
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04464733 | Jul 2020 → May 2023 | chronic hepatitis B virus infection | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05905458 | Jul 2023 → Nov 2024 | chronic hepatitis B virus infection | Chengdu Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS9950 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04464733 ↗ |
| Route | Oral | “Oral HRS9950” NCT04464733 ↗ |